# An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT04250155** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 195 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** XmAb24306
- **DRUG:** Atezolizumab
- **DRUG:** XmAb24306

## Key facts

- **NCT ID:** NCT04250155
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-09
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04250155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04250155, "An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT04250155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*